IDEA4RC FHIR Implementation Guide
0.1.0 - CI Build 150

IDEA4RC FHIR Implementation Guide, published by IDEA4RC Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/hl7-eu/idea4rc/ and changes regularly. See the Directory of published versions

Table of Contents

.. 0 Table of Contents
... 1 IDEA4RC FHIR IG - Home Page
... 2 IDEA4RC Model Overview
... 3 IDEA4RC Detailed ERD Model
... 4 IDEA4RC Logical Models
... 5 Useful Downloads
... 6 Condition-secondaryCancer-eu-i4rc Relationships
... 7 Encounter-eu-i4rc Relationships
... 8 Condition-primaryCancer-eu-i4rc Relationships
... 9 sarcoma-cancer-stage-group Relationships
... 10 hn-cancer-stage-group Relationships
... 11 episodeOfCare-eu-i4rc Relationships
... 12 MedicationAdministration-eu-i4rc Relationships
... 13 Subject Relationships
... 14 PatientFollowUp Relationships
... 15 EpisodeEvent Relationships
... 16 HospitalPatientRecords Relationships
... 17 CancerEpisode Relationships
... 18 AdverseEvent Relationships
... 19 GeneticTestExpression Relationships
... 20 Surgery Relationships
... 21 Radiotherapy Relationships
... 22 Artifacts Summary
.... 22.1 Adverse Event
.... 22.2 Cancer Episode
.... 22.3 Clinical Stage
.... 22.4 Diagnosis
.... 22.5 Disease Extent
.... 22.6 Drugs For Treatments
.... 22.7 Episode Event
.... 22.8 Genetic Test Expression
.... 22.9 Hospital Patient Records
.... 22.10 IsolatedLimbPerfusion
.... 22.11 OverallTreatmentResponse
.... 22.12 Pathological Stage
.... 22.13 Patient
.... 22.14 Patient Follow-Up
.... 22.15 Radiotherapy
.... 22.16 RegionalDeepHyperthemia
.... 22.17 Surgery
.... 22.18 Systemic Treatment
.... 22.19 Adverse Event Model to this guide Map
.... 22.20 Cancer Episode Model to this guide Map
.... 22.21 Clinical Stage Model to this guide Map
.... 22.22 Diagnosis to this guide Map
.... 22.23 Disease Extent Model to this guide Map
.... 22.24 Drugs For Treatments Model to this guide Map
.... 22.25 Episode Event Model to this guide Map
.... 22.26 Genetic Test Expression Model to this guide Map
.... 22.27 Hospital Patient Records Model to this guide Map
.... 22.28 Isolated Limb Perfusion Model to this guide Map
.... 22.29 Overall Treatment Response Model to this guide Map
.... 22.30 Pathological Stage Model to this guide Map
.... 22.31 Patient (Subject) Model to this guide Map
.... 22.32 Patient Follow up Model to this guide Map
.... 22.33 Radiotherapy Model to this guide Map
.... 22.34 Regional Deep Hyperthemia Model to this guide Map
.... 22.35 Surgery Model to this guide Map
.... 22.36 Systemic Treatment Model to this guide Map
.... 22.37 Observation: Alcohol use
.... 22.38 Observation: Cancer Treatment
.... 22.39 Observation: Charlson Comorbidity Index
.... 22.40 Observation: Comorbidities
.... 22.41 Observation: ECOG Performance Status
.... 22.42 Observation: Karnofsky Performance Status
.... 22.43 Observation: Occurrence of the other cancer
.... 22.44 Observation: Tobacco use
.... 22.45 Patient: IDEA4RC
.... 22.46 Condition: Primary Cancer
.... 22.47 Observation: Diagnosis details
.... 22.48 Observation: Head Neck Cancer Stage Group
.... 22.49 Observation: Localized Category (Stage, Sarcoma)
.... 22.50 Observation: LocoRegional Category (Stage)
.... 22.51 Observation: Number of tumor nodules
.... 22.52 Observation: Radiological Extra-nodal extension (rENE)
.... 22.53 Observation: Sarcoma Cancer and Disease Extent Stage Group
.... 22.54 Observation: TNM Distant Metastases Category
.... 22.55 Observation: TNM Primary Tumor Category
.... 22.56 Observation: TNM Regional Nodes Category
.... 22.57 Encounter: IDEA4RC
.... 22.58 Observation: date of the last contact
.... 22.59 Observation: Status at the Last Follow Up
.... 22.60 Procedure: Surgery
.... 22.61 Procedure: Radiotherapy
.... 22.62 MedicationAdministration: Chemotherapy
.... 22.63 EpisodeOfCare: IDEA4RC
.... 22.64 AdverseEvent: IDEA4RC
.... 22.65 Bundle: IDEA4RC
.... 22.66 Condition: Metastatic Cancer
.... 22.67 Observation: Genetic Test Expression
.... 22.68 Observation: Overall Treatment
.... 22.69 Observation: test results
.... 22.70 Observation: Tumor Rupture
.... 22.71 Observation: Yes / No assertions
.... 22.72 Procedure: Immaging for Clinical Stage
.... 22.73 Procedure: Other Treatment
.... 22.74 Substance : Other Treatment
.... 22.75 Adaptive
.... 22.76 Body Location Qualifier
.... 22.77 Chemotherapy Timing
.... 22.78 Condition related to resource
.... 22.79 Histology Morphology Behavior
.... 22.80 Laterality Qualifier
.... 22.81 Medication Outcome
.... 22.82 MedicationAdministration Category
.... 22.83 Performed Timing
.... 22.84 Previous Status
.... 22.85 Procedure Category
.... 22.86 Race Extension
.... 22.87 Radiotherapy Dose Delivered To Volume Extension
.... 22.88 Radiotherapy Energy or Isotope
.... 22.89 Radiotherapy Modality And Technique Extension
.... 22.90 Radiotherapy Modality Extension
.... 22.91 Radiotherapy Number of Sessions Extension
.... 22.92 Radiotherapy Setting
.... 22.93 Radiotherapy Technique Extension
.... 22.94 Relapse Type
.... 22.95 Same custodian flag
.... 22.96 Same Hospital
.... 22.97 Total High Dose Delivered
.... 22.98 Adverse Event Type
.... 22.99 Affected Organs (surgery)
.... 22.100 Alcohol Usage Status: Athena
.... 22.101 Alcohol Usage Status: SNOMED CT
.... 22.102 Antineoplastic and immunostimulating agents
.... 22.103 Beam Quality
.... 22.104 Body site qualifier
.... 22.105 Calculated|Estimated
.... 22.106 Cancer Diagnosis: Athena
.... 22.107 Cancer histology behaviour: Athena
.... 22.108 Cancer histology subgroup: Athena
.... 22.109 Cancer histology: Athena
.... 22.110 Cancer site: Athena
.... 22.111 Cancer Stage Grading: Athena
.... 22.112 Cancer Stage Group Value Clinical: Athena
.... 22.113 Cancer Stage Group Value Pathological: Athena
.... 22.114 Cancer Stage Group Value: Athena
.... 22.115 Cancer Stage Group: Athena
.... 22.116 Chemotherapy cumulative dose units
.... 22.117 Chemotherapy Info
.... 22.118 Clinical TNM Primary Tumor Category Value Set
.... 22.119 Coded test results: Athena.
.... 22.120 Comorbidities: Athena
.... 22.121 Comorbidities: SNOMED
.... 22.122 Country: athena
.... 22.123 Current Smoking Status: Athena
.... 22.124 Disease Status: Athena
.... 22.125 Drugs for Systemic Treatment
.... 22.126 Drugs for Treatments
.... 22.127 ECOG Performance Status
.... 22.128 Event Type
.... 22.129 Extranodal Extension
.... 22.130 Gender: Athena
.... 22.131 Genetic test expression
.... 22.132 Genetic Tests performed (Yes/no/Unk)
.... 22.133 Genito urinary subsite: Athena
.... 22.134 Hypopharynx subsite: Athena
.... 22.135 Hypopharynx subsite: Snomed CT
.... 22.136 Immaging Body sites
.... 22.137 Immaging Clinical Stage
.... 22.138 Immaging Clinical Stage Metastasis
.... 22.139 Immaging Clinical Stage Neck
.... 22.140 Immaging Clinical Stage Primary Site
.... 22.141 Intra abdominal subsite: Athena
.... 22.142 Intra thoracic subsite : Athena
.... 22.143 Larynx subsite: Athena
.... 22.144 Larynx subsite: Snomed CT
.... 22.145 Lip subsite: Athena
.... 22.146 Lip subsite: Snomed CT
.... 22.147 Margins After Surgery
.... 22.148 Metastatis: Athena
.... 22.149 Mitotic Index: Athena.
.... 22.150 Nasal cavity and paranasal sinuses subsite: Athena
.... 22.151 Nasal cavity and paranasal sinuses subsite: Snomed CT
.... 22.152 Nasopharynx subsite: Athena
.... 22.153 Nasopharynx subsite: Snomed CT
.... 22.154 Not Performed|Unknown
.... 22.155 Observation Codes for Distant Metastases Category
.... 22.156 Observation Codes for Primary Tumor Category
.... 22.157 Observation Codes for Regional Node Category
.... 22.158 Occurrence of other cancer
.... 22.159 Oral cavity subsite: Athena
.... 22.160 Oral cavity subsite: Snomed CT
.... 22.161 Oropharynx subsite: Athena
.... 22.162 Oropharynx subsite: Snomed CT
.... 22.163 Other Treatment Procedure Type
.... 22.164 Pathological M
.... 22.165 Pathological N
.... 22.166 Pathological T
.... 22.167 Pathological TNM Primary Tumor Category Value Set
.... 22.168 Positive-Negative-No Test: Athena
.... 22.169 Positive-Negative-No Test: Athena
.... 22.170 Race
.... 22.171 Radiotherapy Device Type
.... 22.172 Radiotherapy Site Laterality Qualifier
.... 22.173 Radiotherapy Sites
.... 22.174 Re-irradiation reason
.... 22.175 Reason to End Treatment
.... 22.176 Regimen
.... 22.177 Sarcoma Staging: localized disease
.... 22.178 Setting Radiotherapy
.... 22.179 Simple measures
.... 22.180 Site of metastasis
.... 22.181 Site rare (IDEA4RC)
.... 22.182 Site: Athena
.... 22.183 Smoking Status: LOINC
.... 22.184 Staging: loco-regional category
.... 22.185 Status at the Last Follow Up
.... 22.186 Subsites: Athena
.... 22.187 Subsites: SNOMED CT
.... 22.188 Surgery Complication
.... 22.189 Surgery Intention
.... 22.190 Surgery Location Qualifier
.... 22.191 Surgery Outcome
.... 22.192 Surgery Site Laterality Qualifier
.... 22.193 Surgery Sites
.... 22.194 Surgical Complications
.... 22.195 Surgical Procedure Category
.... 22.196 Surgical Procedure Type
.... 22.197 TNM Distant Metastases Category Value Set (Clinical)
.... 22.198 TNM Distant Metastases Category Value Set (Pathological)
.... 22.199 TNM Primary Tumor Category Value Set
.... 22.200 TNM Regional Nodes Category Value Set (Clinical)
.... 22.201 TNM Regional Nodes Category Value Set (Pathological)
.... 22.202 Tobacco Product
.... 22.203 Treatment completed as planned
.... 22.204 Treatment Response
.... 22.205 Treatment Setting
.... 22.206 Treatment Technique
.... 22.207 Trunk wall subsite: Athena
.... 22.208 Type of Biopsy
.... 22.209 Type of Diagnosis
.... 22.210 Type of surgical approach
.... 22.211 Type of Systemic Treatment
.... 22.212 Type of Treatment
.... 22.213 Types of Yes/No observations
.... 22.214 Upper and Lower limbs subsite: Athena
.... 22.215 Yes-No-Unk: Athena
.... 22.216 IDEA4RC Body Topography Code System
.... 22.217 IDEA4RC Cancer Diagnosis Code System
.... 22.218 IDEA4RC Code System
.... 22.219 IDEA4RC Vocabulary Code System
.... 22.220 Actor: Head and Neck
.... 22.221 Actor: Sarcoma
.... 22.222 Condition: Grade 2 tumor with several body sites and evidences
.... 22.223 Condition: Metastasis bone and pleura
.... 22.224 Condition: NOT CLEAR WHAT IT REPRESENTS..TO BE DISCUSSED
.... 22.225 Condition: Stable Disease
.... 22.226 encounter-id-14
.... 22.227 EpisodeOfCare
.... 22.228 GOFSH-GENERATED-id-28
.... 22.229 GOFSH-GENERATED-id-30
.... 22.230 GOFSH-GENERATED-id-36
.... 22.231 Observation: Alcohol use
.... 22.232 Observation: BMI
.... 22.233 Observation: C reactive protein Positive
.... 22.234 Observation: Charlson Comorbidity Index
.... 22.235 Observation: comorbidity
.... 22.236 Observation: date of the last contact
.... 22.237 Observation: Diagnosis
.... 22.238 Observation: Dimension of Tumor
.... 22.239 Observation: Distant metastases clinical M1
.... 22.240 Observation: Distant metastases pathology M1
.... 22.241 Observation: ECOG Performance Status score
.... 22.242 Observation: Epstein Barr virus DNA Negative
.... 22.243 Observation: gene Mutation Analysis Performed yes
.... 22.244 Observation: Human papilloma virus Negative
.... 22.245 Observation: immunohiostochemestry analysis performed
.... 22.246 Observation: Karnofsky Performance Status score
.... 22.247 Observation: Number of mitoses per HPF
.... 22.248 Observation: Occurrence of other Cancer: Hamartoma
.... 22.249 Observation: Primary tumor clinical T0
.... 22.250 Observation: Primary tumor pathological T0
.... 22.251 Observation: Radiological Extra-nodal extension
.... 22.252 Observation: Regional lymph nodes Clinical N1
.... 22.253 Observation: Regional lymph nodes pathology N3b
.... 22.254 Observation: Surgery treatment occurred
.... 22.255 Observation: TNM clinical stage grouping
.... 22.256 Observation: TNM pathology stage grouping
.... 22.257 Observation: Tobacco use panel
.... 22.258 Patient: race extension
.... 22.259 Procedure: Isolated limb perfusion